This emerging industry generated $12 Billion in revenues in 2005 and is forecasted to exceed $50 Billion in 2010. In this recent report, AAGP™ was shown to produce significant increases in stem cell viability and competence under both cryopreservation (-80°C) and at refrigeration (+4°C) temperatures.
This analysis consolidates data from previous findings and observed no conflicting observations. Using cryopreservation on a range of both mouse and human embryonic stem cell lines, there was a consistent increase in the viable yield of almost 100% (from 40% to 76%). Other tests show that 96% of the cells remain in an unaffected state indicating that the stem cells are still competent.
These findings show that AAGP™ not only increases cell viability but also maintains cell competence for future use in therapies.
This report and other research data are to be presented to the commercial stem cell storage industry.